http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2016247097-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3769ef50375e4c8a097ac55ddfe42d70 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0036 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 |
| filingDate | 2016-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b0aae45122b4728f86b421f72a7e0b3 |
| publicationDate | 2021-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2016247097-B2 |
| titleOfInvention | Treatment of vaginitis |
| abstract | TREATMENT OF VAGINITIS nABSTRACT nThe invention relates to the treatment of vaginal mycoses, bacterial vaginoses, and other nforms of the vaginitis (inflammation of the vagina). Used externally for this purpose in n5 accordance with the invention is clinoptilolite having a particle size of between 0.2 and n10 im in the treatment of these vaginal disorders in mammals and humans, and also for nrestoring the healthy vaginal microbiota. nThe clinoptilolite may be used with one or more of the following adjuvants: n10 phannaceutically acceptable carrier materials, viable microorganisms and/or extracts nthereof, nutrients for the healthy vaginal microbiota (e.g. lactose, etc.), substances which nfavorably influence the vaginal environment for the healthy vaginal microbiota (e.g. nestradiol, organic acids, etc.). nis The composition used may be applied locally, preferably in one of the following nadministration forms: foam, suppository, vaginal tablet, ovule, gel, aerosol, powder, rinse, ndouche, cream/ointment, suspension. |
| priorityDate | 2015-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 67.